O, B., L, S., OY, B., M, T., NE, B., G, K., . . . M, E. (2025). Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: Multicentre experience in a low-middle-income country. Expert review of anticancer therapy, 25(10), 1213. https://doi.org/10.1080/14737140.2025.2529290
Chicago Style (17th ed.) CitationO, Baş, et al. "Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B: Multicentre Experience in a Low-middle-income Country." Expert Review of Anticancer Therapy 25, no. 10 (2025): 1213. https://doi.org/10.1080/14737140.2025.2529290.
MLA (9th ed.) CitationO, Baş, et al. "Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B: Multicentre Experience in a Low-middle-income Country." Expert Review of Anticancer Therapy, vol. 25, no. 10, 2025, p. 1213, https://doi.org/10.1080/14737140.2025.2529290.
